Patrick Werbrouck
Overview
Explore the profile of Patrick Werbrouck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shore N, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, et al.
Oncologist
. 2024 Feb;
29(7):581-588.
PMID: 38394384
Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen...
2.
Bjartell A, Costa L, Kramer G, Zurawski B, Galli L, Werbrouck P, et al.
Eur Urol Open Sci
. 2022 Nov;
45:12-22.
PMID: 36353661
Background: Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC). Objective: To increase the understanding of real-world treatment pathways...
3.
Tack L, Lefebvre T, Lycke M, Pottel L, Cool L, Ketelaars L, et al.
J Geriatr Oncol
. 2019 Oct;
11(2):320-326.
PMID: 31619371
Objectives: We aimed to determine the proportion of "fit" versus "vulnerable" older patients with cancer included in phase II and III oncology registration trials, as compared to the proportions in...
4.
Lycke M, Lefebvre T, Pottel L, Pottel H, Ketelaars L, Stellamans K, et al.
J Psychosoc Oncol
. 2019 Feb;
37(4):427-440.
PMID: 30798774
Objectives: Cognitive complaints, of objective or subjective nature, may negatively impact cancer patients' quality of life (QoL). Further, the early detection of cognitive alterations may lead to an improved QoL....
5.
Lycke M, Debruyne P, Lefebvre T, Martens E, Ketelaars L, Pottel H, et al.
Acta Clin Belg
. 2017 Oct;
73(2):132-138.
PMID: 29063810
Objective: We previously validated uHear™ to screen for hearing loss in older patients with cancer without a known hearing loss, as part of a comprehensive geriatric assessment (CGA). In view...
6.
Tombal B, Borre M, Rathenborg P, Werbrouck P, van Poppel H, Heidenreich A, et al.
J Urol
. 2017 Sep;
199(2):459-464.
PMID: 28867562
Purpose: A phase 2 study of enzalutamide monotherapy in patients with hormone naïve prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 year and 2 years...
7.
de Bono J, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, et al.
Eur Urol
. 2017 Aug;
74(1):37-45.
PMID: 28844372
Background: Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs...
8.
Lycke M, Lefebvre T, Pottel L, Pottel H, Ketelaars L, Stellamans K, et al.
J Psychosoc Oncol
. 2017 Aug;
35(6):741-757.
PMID: 28816636
Objectives: Research has indicated that cancer-related cognitive impairments (CRCI) may be influenced by psychosocial factors such as distress, worry and fatigue. Therefore, we aimed to validate the distress thermometer (DT)...
9.
Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, et al.
Clin Genitourin Cancer
. 2017 Mar;
15(4):502-508.
PMID: 28258960
Background: Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was...
10.
Lycke M, Pottel L, Pottel H, Ketelaars L, Stellamans K, Van Eygen K, et al.
Psychooncology
. 2016 Jun;
26(5):632-639.
PMID: 27338029
Introduction: Recent research in the field of cancer-related cognitive impairments (CRCI) has shown CRCI presentation prior to treatment initiation. Some have attributed these problems to worry and fatigue, whereas others...